Responses
Clinical science
One year results of a phase 1 study of the safety and tolerability of combination therapy using sustained release intravitreal triamcinolone acetonide and ranibizumab for subfoveal neovascular AMD
Compose a Response to This Article
Other responses
No responses have been published for this article.